Sangamo Biosciences reported $0 in Debt for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Alnylam Pharmaceuticals ALNY:US $ 677.72M 1.01M
Amgen AMGN:US $ 36522M 332M
Avrobio Inc AVRO:US $ 15.1M 84K
Bayer BAYN:GR € 44634M 2087M
Biocryst Pharmaceuticals BCRX:US $ 622.18M 17.72M
Biogen BIIB:US $ 7277.2M 2M
Biomarin Pharmaceutical BMRN:US $ 1081.05M 0.99M
Bluebird Bio BLUE:US $ 0M 0M
GlaxoSmithKline GSK:LN 2211100M 1121700M
Intercept Pharmaceuticals ICPT:US $ 713.86M 3.03M
IONIS PHARMACEUT IONS:US $ 1253.13M 1M
Karyopharm Therapeutics KPTI:US $ 302.69M 202K
Novartis NOVN:VX SF 31031M 244M
Omeros OMER:US $ 314.36M 454K
Regulus Therapeutics RGLS:US $ 4.45M 0.03M
Sangamo Biosciences SGMO:US $ 0M 0M
Sarepta Therapeutics SRPT:US $ 1100.87M 2.03M
Ultragenyx Pharmaceutical RARE:US $ 0M 0M
Vertex Pharmaceuticals VRTX:US $ 482.3M 13.2M
Ziopharm Oncology ZIOP:US $ 24.52M 0.21M